ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
18.49
-0.46 (-2.43%)
At close: Mar 31, 2025, 4:00 PM
17.71
-0.78 (-4.22%)
Pre-market: Apr 1, 2025, 4:22 AM EDT

ArriVent BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-80.49-69.33-36.91-68.81
Asset Writedown & Restructuring Costs
---57.21
Stock-Based Compensation
3.210.90.420.07
Change in Accounts Payable
-0.751.382.80.39
Change in Other Net Operating Assets
7.8211.22-9.95-5.65
Operating Cash Flow
-70.21-55.84-43.63-16.78
Sale (Purchase) of Intangibles
----53.33
Investment in Securities
-192.47---
Investing Cash Flow
-192.47---53.33
Total Debt Issued
---0.27
Total Debt Repaid
----0.27
Issuance of Common Stock
186.580.350.020
Other Financing Activities
--2.41--
Financing Cash Flow
186.5842.86169.72119.82
Net Cash Flow
-76.1-12.98126.0949.71
Levered Free Cash Flow
-48.64-32.8-29.81-
Unlevered Free Cash Flow
-48.64-32.8-29.81-
Change in Net Working Capital
-7.09-12.927.16-
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q